|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, Pin1 inhibition also resulted in decreased phosphorylation of Akt and repressed expression of C-Jun N-terminal kinase and pro-matrix metalloproteinase 2, which were associated closely with the development of melanoma.
|
23067222 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concomitant decreases in vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-2 expression levels, as well as decreased blood vessel density (CD31), were found in tumor samples from PAR-1 siRNA-treated mice, suggesting that PAR-1 is a regulator of melanoma cell growth and metastasis by affecting angiogenic and invasive factors.
|
18974154 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Melanoma A-2058 demonstrated strong expression of MMP-2 and slight expression of MMP-9.
|
28440509 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To better understand the potential impact of these mutant amino acids on protease function and cancer progression, we established a bioinformatics approach to assessing the impact of melanoma mutants, among a previously defined set of extracellular matrix (ECM) structural proteins, on the sensitivity of matrix metalloproteinase-2 (MMP2), extensively associated with melanoma.
|
31019293 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For instance, a RAR alpha antagonist suppressed MMP-1 and MMP-2 synthesis in the melanoma cell line, but not in the FaDu or SCC-25 cells.
|
10415749 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that activation of Jak/Vav/Rho GTPase pathway by CXCL12 is a key signaling event for MT1-MMP/MMP-2-dependent melanoma cell invasion.
|
16397238 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More than 90% tumors expressed alpha6a, beta1, beta3 and beta6 (non-melanoma), and alpha5a, alpha6a and MMP2 (MM).
|
18251742 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of MDA-9/syntenin in melanoma was found to occur in a thrombin-independent signaling pathway and involves the PAR-1/c-Src/Rho GTPases Rac1 and Cdc42/c-Jun N-terminal kinase axis resulting in the activation of paxillin, NF-κB, and matrix metalloproteinase-2 (MMP-2).
|
25505176 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used a bioinformatics approach to assess the impact of amino acid (AA) substitutions on the sensitivity of CECMPs to proteases relevant to melanoma and on the binding affinities for HLA class I. CECMP peptides with AA substitutions overwhelmingly reflect increased sensitivity to proteases implicated in melanoma development (MME, CTSS, MMP2, CTSD, CTSL) in comparison to the wild-type peptide sequences.
|
29047110 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study indicates that microcystin-LR can act as a NF-κB activator to promote MMP-2/-9 expression and melanoma cell invasion, which deserves more environmental health concerns.
|
22992115 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the prognostic value of MMP-2 and Ki-67 via immuno-staining in head and neck melanoma is investigated.
|
25313763 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The melanoma cell lines showed different growth patterns in the brain, and these differences were associated with differences in expression of the angiogenic factors VEGF-A and IL-8 and the matrix metalloproteinases MMP-2 and MMP-9.
|
26667022 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis.
|
16306050 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gelatinase A activity directly modulates melanoma cell adhesion and spreading.
|
7534227 |
1995 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, M21/OPN cells exhibit increased motility, which is markedly reduced upon treatment with inhibitors to alpha(v) and MMP-2.
|
16631740 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Matrix metalloproteinase-2 (MMP-2) has been detected in high levels and correlates with invasiveness in human melanoma.
|
18292932 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, knocking down CD147 attenuates MMP2 response to hypoxia in melanoma cell lines.
|
24090196 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both melanoma cell invasion and MMP-2 activity increased and decreased with EIF5A2 overexpression and knockdown, respectively.
|
24178756 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition.
|
29164766 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation.
|
24246091 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The myriad of biological effects exerted by elastokines on stromal and inflammatory cells led us to hypothesize that they might be main actors in elaborating a favorable cancerization field in melanoma; for instance these peptides could catalyze the vertical growth phase transition in melanoma through increased expression of gelatinase A and membrane-type 1 matrix metalloproteinase.
|
17498549 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When B16-BL6 melanoma cells or Lewis lung carcinoma cells were implanted intradermally, the tumor volumes at 3 weeks after implantation in the gelatinase A-deficient mice decreased by 39% for B16-BL6 melanoma and by 24% for Lewis lung carcinoma (P < 0.03 for each tumor).The number of lung colonies of i.v. injections fell by 54% for B16-BL6 melanoma and 77% for Lewis lung carcinoma (P < 0.014 and P < 0.0015, respectively).
|
9500469 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma.
|
16047212 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This novel mechanism of action of wild-type p53 gene transfer may contribute to its antitumor effect by downregulating cell invasion and matrix metalloproteinase-2 secreted levels in mutated p53 human melanoma cell lines.
|
10844565 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plating cells onto type I or type IV collagen did not trigger pro-MMP-2 activation; on the contrary, conversion of pro-MMP-2 to its active form could be evidenced when melanoma cell lines were seeded in a three dimensional type I collagen lattice.
|
10763911 |
1999 |